Trump’s MMR vaccine split plan may take a decade, experts say

A proposal by former U.S. President Donald Trump to split the combined measles, mumps and rubella (MMR) vaccine into separate doses could face a decade-long delay due to scientific and regulatory challenges, according to public health experts.

The plan, which Trump has promoted as a way to enhance vaccine flexibility and safety monitoring, would require extensive clinical trials to demonstrate the efficacy and safety of individual measles, mumps and rubella vaccines. Current MMR vaccines, which combine all three live attenuated viruses, have been in use for decades and are widely regarded as safe and effective.

Public health officials and vaccine manufacturers have raised concerns about the feasibility of the proposal. Splitting the vaccine would necessitate new regulatory approvals, additional manufacturing processes, and potential changes to vaccination schedules. The U.S. Food and Drug Administration (FDA) would need to evaluate the safety and efficacy of the separated vaccines independently, a process that typically spans years, experts noted.

Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, stated that the combined MMR vaccine has a proven track record of safety and efficacy, and that splitting it could introduce new risks. "The current vaccine is highly effective and has been used safely for generations," Offit said. "Any change would require rigorous testing to ensure it doesn’t compromise protection or increase side effects."

The proposal also raises logistical challenges, including supply chain adjustments and potential disruptions to vaccination programs. Health systems would need to adapt to new dosing schedules, which could complicate efforts to maintain high vaccination rates, particularly in low-resource settings.

While Trump has framed the plan as a step toward personalized medicine, critics argue that the benefits are unclear and the risks substantial. The World Health Organization (WHO) and other global health bodies continue to endorse the combined MMR vaccine as the standard for measles, mumps and rubella prevention.

The timeline for such a change remains uncertain, with experts emphasizing that even under accelerated regulatory pathways, the process would likely extend well beyond a single presidential term.